FDA clearance for clinical surveillance solution
pharmafile | March 16, 2022 | News story | Research and Development |
The latest Philips Capsule Surveillance solution has received market clearance from the FDA, paving the way for widespread deployment across the healthcare system in the US. The capsule can enable doctors to monitor patient data, condition and alarms from devices, virtually from anywhere, thus reducing the chance of infection to staff in case of infectious patients.
The clinical surveillance solution is designed to identify emergent patient deterioration, and offer enhanced patient data visibility, flexible viewing options, and clinical decision support. Philips designed the system to accumulate patient data, and analyse it to generate actionable insights and alerts, and send notifications to caregivers, so that they can intervene before patient deterioration is able to progress further.
“This FDA clearance of the latest release of clinical surveillance solution enables more integrated viewing options within EMR and HIT tools through the secure web-based user interface,” said Elad Benjamin, General Manager of Clinical Data Services at Philips. “The updated intended use provides flexible deployment configurations that Philips Capsule can offer to hospitals and health systems in the USA.”
The system can allow for early identification of deteriorating patient conditions, which can help to avoid complications and escalations. This aims to increase the standard of patient care while also reducing the cost of care. The ability to remotely monitor large numbers of patients, also focusing resources where needed, may also help manage shortages of experienced clinicians.
Elad Benjamin concluded: “Properly implemented clinical surveillance has the potential to significantly improve patient outcomes by helping to avoid deterioration, while also improving the care team experience via clinical decision support and minimizing the burden of false and clinically unactionable alarms.”
Ana Ovey
